Scott Bailey, MD
Obstetrics & Gynecology · Fayetteville, ARNPI 1477528867
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Minerva Surgical, Inc at 52.0% of the total. Reporting peaked in 2019 at $3,539 and has fallen 83.2% since, to $596 in 2025.
Across 150 payments — averaging $43.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Minerva Surgical, Inc$3K
- AbbVie$952
- Astellas Pharma US Inc$365
- Caldera Medical, Inc$222
- Mayne Pharma Commercial LLC$171
- Pfizer$154
- plus $1K from 21 others
What the payments were for
- Consulting fees$2,70041%
- Speaking & faculty fees$3005%
- Food & beverage$3,55354%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Minerva Surgical, Inc | 8 | $3,418 |
| AbbVie(2 entities) | 57 | $952 |
| Astellas Pharma US Inc | 9 | $365 |
| Caldera Medical, Inc | 2 | $222 |
| Mayne Pharma Commercial LLC | 5 | $171 |
| Pfizer | 11 | $154 |
| Hologic Sales And Service, LLC | 7 | $133 |
| Organon | 7 | $127 |
| Sumitomo Pharma America, Inc. | 7 | $123 |
| Baxter Healthcare | 2 | $111 |
| Medtronic | 3 | $97 |
| Coloplast | 4 | $92 |
| Biogen | 4 | $92 |
| Johnson & Johnson | 1 | $81 |
| Millicent US Inc | 4 | $78 |
| Exeltis, USA Inc. | 4 | $67 |
| Pacira Pharmaceuticals Incorporated | 1 | $48 |
| Myovant Sciences Inc. | 2 | $47 |
| Bayer | 2 | $38 |
| Covidien LP | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Mylan Pharmaceuticals Inc. | 1 | $22 |
| Coopersurgical, Inc. | 1 | $20 |
| Medline Industries LP | 1 | $16 |
| Urovant Sciences Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Meditrina | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Endometrial Ablation System (Device)$3,104
- Veozah$246
- NEXTSTELLIS$101
- Orilissa$101
How this compares
$6,567 in reported general payments places this provider in the 85th percentile of 272 obstetrics & gynecology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 16 | $11,778 |
| PremarinEstrogens, Conjugated | 13 | $7,540 |
| Estradiol | 397 | $4,519 |
| ProgesteroneProgesterone, Micronized | 96 | $2,275 |
| DottiEstradiol | 25 | $1,969 |
| Estradiol (Once Weekly)Estradiol | 18 | $1,069 |
| Tolterodine Tartrate ErTolterodine Tartrate | 29 | $1,022 |
| Levothyroxine Sodium | 95 | $933 |
| Estradiol (Twice Weekly)Estradiol | 16 | $727 |
| ValacyclovirValacyclovir Hcl | 17 | $663 |
| Clobetasol Propionate | 15 | $635 |
| LyllanaEstradiol | 11 | $620 |
| Medroxyprogesterone Acetate | 82 | $499 |
| Metronidazole | 18 | $305 |
| Ibandronate Sodium | 20 | $277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $365 | $11,77816 claims |
| PfizerPremarin | $154 | $7,54013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 obstetrics & gynecology providers in Arkansas.
Other obstetrics & gynecology in Fayetteville
- Erin LargeFayetteville$16K
- Jason HurtFayetteville$11K
- Michael CopeLittle Rock$147K
- Jeanmarie HouseholderFort Smith$140K
- Timothy BellFort Smith$53K
- Paige PartridgeJohnson$50K
- David ShenkerLittle Rock$28K
- Christopher TaylorHarrison$24K
- Julia GoodwinLittle Rock$16K
- Lisa WatermanSpringdale$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.